|
Provectus Biopharmaceuticals Inc (PVCT) |
|
Provectus Biopharmaceuticals Inc
PVCT's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Provectus Biopharmaceuticals Inc growth rates, revenue grew
by 57.38 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 3202
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Provectus Biopharmaceuticals Inc net loss increased from $-1 millions, to $-1 millions in III. Quarter 2024,
• More on PVCT's Growth
|
|
Provectus Biopharmaceuticals Inc realized a net loss in trailing twelve months.
Provectus Biopharmaceuticals Inc realized cash reduction of $ -0 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 55.68.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.18.
• More on PVCT's Valuation
|
|
|
|
|
Provectus Biopharmaceuticals Inc realized net loss in trailing twelve months.
Provectus Biopharmaceuticals Inc realized cash outflow of $ -0per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 55.68.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.18.
• More on PVCT's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com